Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity
Iranian Journal of Pharmaceutical Research · 09.08.2023 · 22 (1)
DOI: 10.5812/ijpr-131015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 09.08.2023. Verfasst von Changzhen Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ningbo No.2 Hospital, Ningbo, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Fibroblast growth factor 21 (FGF21) is a metabolic, endocrine hormone regulating insulin sensitivity, energy expenditure, and lipid metabolism. It has significant potential as a therapeutic drug for treating type 2 diabetes and obesity. However, the clinical efficacy of FGF21 analogs is limited due to their instability and short half-life. Glucagon-like peptide 1 (GLP-1) receptor agonists have been recognized as effective medications for type 2 diabetes mellitus and obesity over the past two decades.
Methods
This study designed a new long-acting dual-agonist, exendin-4/FGF21, utilizing albumin-binding-designed ankyrin repeat proteins (DARPins) as carriers. The purified fusion proteins were subcutaneously injected into mice for pharmacokinetic and biological activity studies.
Results
Ex-DARP-FGF21 had a high binding affinity for human serum albumin (HSA) in vitro and a prolonged half-life of 27.6 hours in vivo. Bioactivity results reveal that Ex-DARP-FGF21 significantly reduced blood glucose levels in healthy mice. Moreover, compared to Ex-DARP alone, the Ex-DARP-FGF21 dual agonist displayed enhanced blood glucose lowering bioactivity and superior body weight management in the diet-induced obesity (DIO) mouse model.
Conclusions
These results indicate that the long-acting dual agonist of exendin-4 and FGF21 holds considerable potential as a treatment for type 2 diabetes mellitus (T2DM) and obesity in the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Ningbo No.2 Hospital, Ningbo, China.
- Department of Clinical Laboratory, Ningbo No.2 Hospital, Ningbo, China.
- Department of Pharmacology, Duchuangsanzhong Biotech Co., Ltd., Jiaxing, China.
- Department of Endocrinology, Ningbo No.2 Hospital, Ningbo, China.
- Department of Science and Education, Ningbo No.2 Hospital, Ningbo, China.
Zitieren
APA
Zhang, C., Gao, G., Li, Y., Ying, J., Li, J., & Hu, S. (2023). Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity. Iranian Journal of Pharmaceutical Research, 22(1). https://doi.org/10.5812/ijpr-131015
Vancouver
Zhang C, Gao G, Li Y, Ying J, Li J, Hu S. Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity. Iranian Journal of Pharmaceutical Research. 2023;22(1). doi:10.5812/ijpr-131015
BibTeX
@article{Zhang2023,
author = {Zhang, Changzhen and Gao, Guosheng and Li, Yafeng and Ying, Jingjing and Li, Jianhui and Hu, Supei},
title = {Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2023},
volume = {22},
number = {1},
doi = {10.5812/ijpr-131015}
}
EUVIMED